Published in Ann Surg Oncol on April 19, 2005
Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol (2009) 23.08
Prognostic significance of mitotic rate in localized primary cutaneous melanoma: an analysis of patients in the multi-institutional American Joint Committee on Cancer melanoma staging database. J Clin Oncol (2011) 1.78
Changes in the presentation of nodular and superficial spreading melanomas over 35 years. Cancer (2008) 1.14
Predictors of sentinel lymph node metastasis in melanoma. Can J Surg (2010) 1.11
Importance of sentinel lymph node biopsy in patients with thin melanoma. Arch Surg (2008) 1.10
Meta-analysis of sentinel lymph node positivity in thin melanoma (<or=1 mm). Cancer (2009) 1.03
Melanoma sentinel node biopsy and prediction models for relapse and overall survival. Br J Cancer (2010) 0.99
Clark level risk stratifies patients with mitogenic thin melanomas for sentinel lymph node biopsy. Ann Surg Oncol (2013) 0.93
Predictors of occult nodal metastasis in patients with thin melanoma. Arch Surg (2010) 0.90
Melanoma in pediatric, adolescent, and young adult patients. Semin Oncol (2009) 0.89
Pump-probe imaging of pigmented cutaneous melanoma primary lesions gives insight into metastatic potential. Biomed Opt Express (2015) 0.86
Sentinel node biopsy is indicated for thin melanomas ≥0.76 mm. Ann Surg Oncol (2012) 0.85
Surgery and sentinel lymph node biopsy. Semin Oncol (2007) 0.85
Outcome of sentinel lymph node biopsy and prognostic implications of regression in thin malignant melanoma. Melanoma Res (2012) 0.82
Early-stage non-Spitzoid cutaneous melanoma in patients younger than 22 years of age at diagnosis: long-term follow-up and survival analysis. J Pediatr Surg (2015) 0.79
Tumor Cell Adhesion As a Risk Factor for Sentinel Lymph Node Metastasis in Primary Cutaneous Melanoma. J Clin Oncol (2015) 0.77
Chinese Guidelines on the Diagnosis and Treatment of Melanoma (2015 Edition). Ann Transl Med (2015) 0.76
Update and Review on the Surgical Management of Primary Cutaneous Melanoma. Healthcare (Basel) (2014) 0.75
Established and Emerging Biomarkers in Cutaneous Malignant Melanoma. Healthcare (Basel) (2014) 0.75
[Mitosis in early invasive malignant melanoma. How reliable is histogenetic classification at stage pT1?]. Pathologe (2012) 0.75
Identification of Patients with Intermediate Thickness Melanoma at Low Risk for Sentinel Lymph Node Positivity. Ann Surg Oncol (2015) 0.75
Prognosis of patients with melanoma and microsatellitosis undergoing sentinel lymph node biopsy. Ann Surg Oncol (2013) 0.75
Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol (2009) 23.08
Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med (2003) 16.62
Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell (2010) 12.50
Akt stimulates aerobic glycolysis in cancer cells. Cancer Res (2004) 9.35
microRNAs exhibit high frequency genomic alterations in human cancer. Proc Natl Acad Sci U S A (2006) 8.24
The microRNAs miR-373 and miR-520c promote tumour invasion and metastasis. Nat Cell Biol (2008) 7.86
A tumorigenic subpopulation with stem cell properties in melanomas. Cancer Res (2005) 7.86
Treatment-responsive limbic encephalitis identified by neuropil antibodies: MRI and PET correlates. Brain (2005) 6.81
Genomic and epigenetic alterations deregulate microRNA expression in human epithelial ovarian cancer. Proc Natl Acad Sci U S A (2008) 4.79
Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and T(reg) cells. Nature (2011) 4.07
Constitutive mitogen-activated protein kinase activation in melanoma is mediated by both BRAF mutations and autocrine growth factor stimulation. Cancer Res (2003) 4.03
Genome-wide association study identifies three loci associated with melanoma risk. Nat Genet (2009) 3.89
Anticonvulsant medications and the risk of suicide, attempted suicide, or violent death. JAMA (2010) 3.85
Common sequence variants on 20q11.22 confer melanoma susceptibility. Nat Genet (2008) 3.79
Variability in nomenclature used for nevi with architectural disorder and cytologic atypia (microscopically dysplastic nevi) by dermatologists and dermatopathologists. J Cutan Pathol (2004) 3.43
Endothelin B receptor mediates the endothelial barrier to T cell homing to tumors and disables immune therapy. Nat Med (2008) 3.35
Breast cancer detection based on incremental biochemical and physiological properties of breast cancers: a six-year, two-site study. Acad Radiol (2005) 3.33
Skeletal PET with 18F-fluoride: applying new technology to an old tracer. J Nucl Med (2007) 3.08
Serum 25-hydroxyvitamin D3 levels are associated with breslow thickness at presentation and survival from melanoma. J Clin Oncol (2009) 2.85
MC1R germline variants confer risk for BRAF-mutant melanoma. Science (2006) 2.84
Diffuse optical tomography of breast cancer during neoadjuvant chemotherapy: a case study with comparison to MRI. Med Phys (2005) 2.76
Leukemia-associated NOTCH1 alleles are weak tumor initiators but accelerate K-ras-initiated leukemia. J Clin Invest (2008) 2.73
Genome-wide association study identifies variants at 9p21 and 22q13 associated with development of cutaneous nevi. Nat Genet (2009) 2.65
Randomized multicenter trial of hyperthermic isolated limb perfusion with melphalan alone compared with melphalan plus tumor necrosis factor: American College of Surgeons Oncology Group Trial Z0020. J Clin Oncol (2006) 2.60
Hypoxia-inducible factor 2alpha regulates macrophage function in mouse models of acute and tumor inflammation. J Clin Invest (2010) 2.48
18-fluorodeoxyglucose positron emission tomographic imaging in the detection and monitoring of infection and inflammation. Semin Nucl Med (2002) 2.45
Overcoming intrinsic multidrug resistance in melanoma by blocking the mitochondrial respiratory chain of slow-cycling JARID1B(high) cells. Cancer Cell (2013) 2.43
High-risk melanoma susceptibility genes and pancreatic cancer, neural system tumors, and uveal melanoma across GenoMEL. Cancer Res (2006) 2.40
Evolution of sleep quantity, sleep deprivation, mood disturbances, empathy, and burnout among interns. Acad Med (2006) 2.39
Inherited mutations in pheochromocytoma and paraganglioma: why all patients should be offered genetic testing. Ann Surg Oncol (2013) 2.38
An atypical melanocytic lesion without genomic abnormalities shows locoregional metastasis. J Cutan Pathol (2012) 2.31
Genome-wide association study identifies three new melanoma susceptibility loci. Nat Genet (2011) 2.29
Targeting HER-2/neu in early breast cancer development using dendritic cells with staged interleukin-12 burst secretion. Cancer Res (2007) 2.25
Features associated with germline CDKN2A mutations: a GenoMEL study of melanoma-prone families from three continents. J Med Genet (2006) 2.17
Melanoma adapts to RAF/MEK inhibitors through FOXD3-mediated upregulation of ERBB3. J Clin Invest (2013) 2.11
Impact of implementation of a pediatric surgery fellowship on general surgery resident operative volume. J Surg Educ (2012) 2.10
Identification of high-risk patients among those diagnosed with thin cutaneous melanomas. J Clin Oncol (2007) 2.06
Identifying individuals at high risk of melanoma: a practical predictor of absolute risk. J Clin Oncol (2006) 2.05
Comparison of 123I scintigraphy at 5 and 24 hours in patients with differentiated thyroid cancer. J Nucl Med (2002) 2.05
Diet and melanoma in a case-control study. Cancer Epidemiol Biomarkers Prev (2004) 2.05
Time of day is associated with postoperative morbidity: an analysis of the national surgical quality improvement program data. Ann Surg (2008) 2.00
Importance of surveillance for multiple endocrine neoplasia-1 and surgery in patients with sporadic Zollinger-Ellison syndrome. Clin Gastroenterol Hepatol (2012) 2.00
KLF17 is a negative regulator of epithelial-mesenchymal transition and metastasis in breast cancer. Nat Cell Biol (2009) 1.97
Impact of FDG PET on the preoperative staging of newly diagnosed breast cancer. Eur J Nucl Med Mol Imaging (2007) 1.93
Diagnosis and localization of focal congenital hyperinsulinism by 18F-fluorodopa PET scan. J Pediatr (2007) 1.92
Thin primary cutaneous malignant melanoma: a prognostic tree for 10-year metastasis is more accurate than American Joint Committee on Cancer staging. J Clin Oncol (2004) 1.90
Aggressive squamous cell carcinomas in persons infected with the human immunodeficiency virus. Arch Dermatol (2002) 1.90
Systemic and vascular inflammation in patients with moderate to severe psoriasis as measured by [18F]-fluorodeoxyglucose positron emission tomography-computed tomography (FDG-PET/CT): a pilot study. Arch Dermatol (2011) 1.88
Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E-mutated melanomas. Mol Cancer Ther (2008) 1.86
Application of a BRAF pyrosequencing assay for mutation detection and copy number analysis in malignant melanoma. J Mol Diagn (2007) 1.85
The SNMMI practice guideline for therapy of thyroid disease with 131I 3.0. J Nucl Med (2012) 1.84
Differentiation of benign and malignant breast tumors by in-vivo three-dimensional parallel-plate diffuse optical tomography. J Biomed Opt (2009) 1.82
Prognostic significance of mitotic rate in localized primary cutaneous melanoma: an analysis of patients in the multi-institutional American Joint Committee on Cancer melanoma staging database. J Clin Oncol (2011) 1.78
Ductal carcinoma in situ: state of the science and roadmap to advance the field. J Clin Oncol (2008) 1.74
MC1R variants increase risk of melanomas harboring BRAF mutations. J Invest Dermatol (2008) 1.72
Radioimmunotherapy of non-Hodgkin's lymphoma with 90Y-DOTA humanized anti-CD22 IgG (90Y-Epratuzumab): do tumor targeting and dosimetry predict therapeutic response? J Nucl Med (2003) 1.71
Detecting and targeting mesenchymal-like subpopulations within squamous cell carcinomas. Cell Cycle (2011) 1.70
Changes in the surgical management of patients with breast carcinoma based on preoperative magnetic resonance imaging. Cancer (2003) 1.70
Mist1-KrasG12D knock-in mice develop mixed differentiation metastatic exocrine pancreatic carcinoma and hepatocellular carcinoma. Cancer Res (2006) 1.69
Utility of FDG-PET scanning in lymphoma by WHO classification. Blood (2003) 1.69
State of the art, nomenclature, and points of consensus and controversy concerning benign melanocytic lesions: outcome of an international workshop. Adv Anat Pathol (2010) 1.68
Pathology review of cases presenting to a multidisciplinary pigmented lesion clinic. Arch Dermatol (2002) 1.68
Dynamic changes of FDG uptake and clearance in normal tissues. Mol Imaging Biol (2013) 1.66
Diagnosing and managing cutaneous pigmented lesions: primary care physicians versus dermatologists. J Gen Intern Med (2006) 1.65
Diffuse optical measurement of blood flow in breast tumors. Opt Lett (2005) 1.65
Morbidity and mortality of colorectal carcinoma surgery differs by insurance status. Cancer (2004) 1.64
A polymorphism in the agouti signaling protein gene is associated with human pigmentation. Am J Hum Genet (2002) 1.63
PET in the management of urologic malignancies. Radiol Clin North Am (2004) 1.62
Dual time point 18F-FDG PET for the evaluation of pulmonary nodules. J Nucl Med (2002) 1.60
Paraneoplastic cerebellar degeneration: Yo-expressing tumor revealed after a 5-year follow-up with FDG-PET. J Neurol Sci (2006) 1.57
Tumor vascular proteins as biomarkers in ovarian cancer. J Clin Oncol (2007) 1.55
Assessment of atherosclerosis in large vessel walls: A comprehensive review of FDG-PET/CT image acquisition protocols and methods for uptake quantification. J Nucl Cardiol (2015) 1.53
18F-FDG uptake in lung, breast, and colon cancers: molecular biology correlates and disease characterization. J Nucl Med (2009) 1.52
Hypoxia induces phenotypic plasticity and therapy resistance in melanoma via the tyrosine kinase receptors ROR1 and ROR2. Cancer Discov (2013) 1.52
Functional imaging of inflammatory diseases using nuclear medicine techniques. Semin Nucl Med (2009) 1.51
Rapid high efficiency sensitization of CD8+ T cells to tumor antigens by dendritic cells leads to enhanced functional avidity and direct tumor recognition through an IL-12-dependent mechanism. J Immunol (2003) 1.50
Are en face frozen sections accurate for diagnosing margin status in melanocytic lesions? Am J Clin Pathol (2003) 1.50
The rise in metastasectomy across cancer types over the past decade. Cancer (2014) 1.49
Resection of primary leiomyosarcoma of the inferior vena cava (IVC) with reconstruction: a case series and review of the literature. J Surg Oncol (2014) 1.49